(VIANEWS) – At 15:47 EST on Friday, shares of AFFLUENT MEDICAL (AFME.PA) plummeted by 22.29% to EUR1.36 at 15:47 ET, reversing three consecutive sessions of gains. Meanwhile, CAC 40 increased by 1.47% to EUR7,415.99 which indicates an upward trend across markets today.
AFFLUENT MEDICAL recently closed at EUR1.75, 46.56% below its 52-week high of EUR3.28.
About AFFLUENT MEDICAL
Affluent Medical SA of Aix-en-Provence, France specializes in developing and manufacturing minimally invasive solutions to treat heart and vascular diseases. Their primary products include Kardiozis technology for abdominal aortic aneurysm treatment; Kalios and Epygon implants for mitral insufficiency treatment; Artus implant for severe urinary incontinence treatment in both men and women. Established in 2011, Affluent Medical continues to innovate cutting-edge medical technologies that improve lives through cutting edge medical technologies that improve lives through innovation.
Yearly Analysis
Data indicates that AFFLUENT MEDICAL’s stock is currently trading at EUR1.36, below its 52-week high of EUR3.28 but higher than its low of EUR1.10. This suggests a substantial drop in value over the past year.
Investors should take note that the current price is lower than its 52-week high, which could indicate it may be undervalued. But still, its recovery suggests it has experienced some improvement.
Overall, investors must carefully examine both a stock’s past performance and current market conditions prior to making any investment decisions.
Technical Analysis
AFFLUENT MEDICAL’s stock is currently trading above its 50-day moving average of EUR1.23, but below its 200-day moving average of EUR1.48, indicating a mixed short and long-term trend. Furthermore, 72,298 orders were placed with them recently compared to their average volume of 7,675, signalling high trading activity.
As for AFFLUENT MEDICAL’s volatility, its current intraday variation average for the past week, month, and quarter is 22.14%; these values represent its highest amplitude of average volatility: 22.14% last week; 4.63% in month; and 2.69% quarterly.
The stochastic oscillator, an effective indicator of overbought and oversold conditions, classifies AFFLUENT MEDICAL’s stock as oversold (=20). This suggests it could be undervalued and due for a rebound.
Quarter Analysis
According to available information, this stock has experienced a decrease in year-on-year quarterly revenue growth by 25.8% since 2012. Twelve trailing months’ revenues show 1.34M.
As such, investors should remain wary of a stock’s revenue growth potential. A drop of 25.8% would signal trouble with operations or market conditions at play for this company.
However, revenue growth doesn’t tell the whole story. Investors should also take into account other aspects like profitability, competitive positioning and overall market trends when making investment decisions. An analysis of company finances, management practices and industry trends should precede making any definitive investments decisions.
Equity Analysis
According to AFFLUENT MEDICAL’s financial information, their trailing twelve month EPS (Earnings Per Share) is negative at EUR-1.35 indicating losses over the previous year and perhaps insufficient earnings generation to provide enough rewards for shareholders.
Return on Equity (ROE) for the last twelve trailing months was negative at -39.36%. This indicates that shareholders’ investments are not yielding sufficient returns, suggesting financial issues or ineffective use of resources may exist within the organization. A negative ROE should serve as a warning sign to investors as it suggests there could be potential problems ahead.
Overall, AFFLUENT MEDICAL’s negative EPS and ROE figures signal potential problems with its financial health. Investors should take great caution when making any investment decisions regarding this company and conduct additional research before making their choice.
More news about AFFLUENT MEDICAL (AFME.PA).
